Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Blood

Volumn 128, Issue 11, 2016, Pages 1458-1464

  Kumar, Anita ^a   Casulo, Carla ^b   Yahalom, Joachim ^a   Schöder, Heiko ^a   Barr, Paul M ^b   Caron, Philip ^a   Chiu, April ^a   Constine, Louis S ^b   Drullinsky, Pamela ^a   Friedberg, Jonathan W ^b   Gerecitano, John F ^a   Hamilton, Audrey ^a   Hamlin, Paul A ^a   Horwitz, Steven M ^a   Jacob, Alexandra G ^a   Matasar, Matthew J ^a   McArthur, Gianna N ^a   McCall, Susan J ^a   Moskowitz, Alison J ^a   Noy, Ariela ^a   Palomba, Maria L ^a   Portlock, Carol S ^a   Straus, David J ^a   VanderEls, Nicholas ^a   Verwys, Stephanie L ^a   Yang, Joanna ^a   Younes, Anas ^a   Zelenetz, Andrew D ^a   Zhang, Zhigang ^a   Moskowitz, Craig H ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CARBOPLATIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FILGRASTIM; IFOSFAMIDE; VINBLASTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DEAUVILLE SCORE; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SCORING SYSTEM; SENSORY NEUROPATHY; TREATMENT RESPONSE; TUMOR BIOPSY; ADOLESCENT; CANCER STAGING; CHEMORADIOTHERAPY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DACARBAZINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; VINBLASTINE; YOUNG ADULT;

EID: 84988328541     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-703470     Document Type: Article

References (30)

1. Hoppe RT, Advani RH, Ai WZ, et al; National Comprehensive Cancer Network. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; 10(5):589-597.
2. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015; 372(17):1598-1607.
3. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12): 1188-1194.
4. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357(19):1916-1927.
5. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199-4206.
6. Advani RH, Hong F, Fisher RI, et al. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015;33(17):1936-1942.
7. Ng AK, Bernardo MVP, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002; 100(6):1989-1996.
8. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7): 640-652.
9. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79(3):270-277.
10. Specht L, Yahalom J, Illidge T, et al; ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854-862.
11. Oki Y, Younes A. Brentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther. 2012; 12(5):623-632.
12. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011;17(20): 6428-6436.
13. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19):1812-1821.
14. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, doseescalation study. Lancet Oncol. 2013;14(13): 1348-1356.
15. Connors JM, Ansell SM, Park SI, Fanale MA, Younes A. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin lymphoma: long term outcomes [abstract]. Blood. 2014;124(21). Abstract 292.
16. Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127(18):2189-2192.
17. Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol. 1994;12(2): 297-305.
18. Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol. 1996;14(4):1297-1305.
19. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005;23(30):7614-7620.
20. Blum KA, Jung SH, Johnson JL, et al; Cancer and Leukemia Group B. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgRIIIa-158 V/F polymorphism. Ann Oncol. 2010;21(11): 2246-2254.
21. Specht L, Yahalom J. The concept and evolution of involved site radiation therapy for lymphoma. Int J Clin Oncol. 2015;20(5):849-854.
22. Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99(6):1107-1113.
23. Gaensler EA, Wright GW. Evaluation of respiratory impairment. Arch Environ Health. 1966;12(2):146-189.
24. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-187.
25. Kumar A, Burger IA, Zhang Z, et al. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes [published online ahead of print July 6, 2016]. Haematologica. doi:10.3324/haematol.2016.141846.
26. Straus D, Pitcher BN, Kostakoglu L, et al. Initial results of US Intergroup Trial of responseadapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB/Alliance 50604) [abstract]. Blood. 2015;126(23). Abstract 578.
27. Simontacchi G, Filippi AR, Ciammella P, Ricardi U. Interim PET after two ABVD cycles in earlystage Hodgkin lymphoma: outcomes following the continuation of chemotherapy plus radiotherapy. In reply to Adams and Kwee. Int J Radiat Oncol Biol Phys. 2015;93(3):725-726.
28. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91(4): 475-481.
29. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907-913.
30. Savage KJ, Connors JM, Villa DR, et al. Advanced stage classical Hodgkin lymphoma patients with a negative PET-scan following treatment with ABVD have excellent outcomes without the need for consolidative radiotherapy regardless of disease bulk at presentation [abstract]. Blood. 2015;126(23). Abstract 579.